ALX Oncology Holdings Inc. (ALXO), a clinical-stage biotechnology company based in Redwood City, California, develops next-generation immuno-oncology therapies led by evorpacept (ALX148), an Fc-silenced CD47-blocking fusion protein, and ALX2004, an EGFR (epidermal growth factor receptor)-targeted antibody-drug conjugate. The central question for investors is whether the stock, trading near $1.28, can climb to a $4.50 price target.
Five valid analyst price targets were reviewed, ranging from a low of $4.00 to a high of $6.00. The arithmetic mean is $4.60, which rounds to the $4.50 central target used throughout this article. The overall rating consensus is bullish, with the majority of covering analysts at Buy or equivalent, while LifeSci Capital holds a more cautious Hold rating without a published target.
The spread between the lowest ($4.00) and highest ($6.00) targets is wide, which is typical for a pre-revenue biotech whose valuation hinges on future clinical data rather than current earnings. UBS has maintained its $6.00 Buy target on a "de-risked CD47 program and upcoming catalysts," while H.C. Wainwright and Piper Sandler anchor the lower end at $4.00 on evorpacept's biomarker-driven potential. These targets are analyst expectations, not guarantees, and they reflect a roughly 12-month research horizon rather than a near-term prediction.
As of early November 2026, ALXO trades near $1.28, with a market capitalization of roughly $178 million and a 52-week range of approximately $0.86 to $2.66. Reaching $4.50 would require a gain of about 250%, a very large move by any standard and one that would depend almost entirely on positive clinical catalysts.
There is no established profitability to support a traditional valuation. The company reported a GAAP (generally accepted accounting principles) net loss of about $18 million in its most recent quarter, and consensus estimates point to a full-year 2026 EPS (earnings per share) loss of roughly $0.56. The path toward the target therefore runs through data readouts, notably the Phase 2 ASPEN-09-Breast trial, and any subsequent regulatory discussions, rather than near-term financial results.
The stock sits well below its 52-week high of about $2.66, which now functions as a notable resistance zone, alongside the psychological $2.00 level. On the downside, the 52-week low near $0.86 and the $1.00 round-number level represent key support areas. A decisive move above $2.66 would mark a meaningful structural shift, but the gap to $4.50 remains substantial.
Analyst price targets generally reflect a roughly 12-month outlook, and the $4.50 figure sits within that framework. Key items to watch include the mid-2027 ASPEN-09-Breast topline data, ALX2004 dose-escalation results, potential FDA (Food and Drug Administration) interactions on a Phase 3 design, and progress on the companion diagnostic being developed with Ventana. Quarterly cash-burn updates and any financing activity will also shape the path.
AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, catalyst-dependent name like ALX Oncology, this kind of automated signal can help traders spot shifting momentum more efficiently than manual chart review. Traders can use it to discover new opportunities, monitor existing positions, and identify changing trends as they develop. Consider exploring the AI Daily Buy/Sell Signals to see how AI-driven insight can complement your own research.
The $4.50 central target, derived from a $4.60 average of five analyst price targets, implies a roughly 250% move from a price near $1.28 — a very large step that depends on clinical success rather than current fundamentals. The bullish case rests on compelling biomarker-driven CD47 data and a runway into mid-2028, while the bearish case centers on the company's pre-revenue status and binary upcoming readouts. With targets spanning $4.00 to $6.00, analysts clearly disagree on the scale of the opportunity. Investors should monitor the ASPEN-09-Breast data, ALX2004 progress, and cash position before drawing conclusions about whether the target is achievable.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ALXO has been loosely correlated with MDGL. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ALXO jumps, then MDGL could also see price increases.
| Ticker / NAME | Correlation To ALXO | 1D Price Change % | ||
|---|---|---|---|---|
| ALXO | 100% | -13.62% | ||
| MDGL - ALXO | 56% Loosely correlated | -0.04% | ||
| AXON - ALXO | 45% Loosely correlated | -0.21% | ||
| AMRN - ALXO | 43% Loosely correlated | +0.09% | ||
| ARVN - ALXO | 38% Loosely correlated | +2.37% | ||
| FHTX - ALXO | 37% Loosely correlated | -6.86% | ||
More | ||||